ライフサイエンスコーパス: hepatic steatosis

1 hat cause lipid accumulation in hepatocytes (hepatic steatosis).

2 le risk factors lead to a high likelihood of hepatic steatosis.

3 ic hepatic sympathetic overactivity mediates hepatic steatosis.

4 improves glucose homeostasis, and attenuates hepatic steatosis.

5 d were protected from insulin resistance and hepatic steatosis.

6 diet resulted in significant improvement in hepatic steatosis.

7 is (DNL) in response to carbohydrates and in hepatic steatosis.

8 t from the risk in a clinical cohort without hepatic steatosis.

9 ssion was also independently associated with hepatic steatosis.

10 o completed liver ultrasound examination for hepatic steatosis.

11 lop glucose intolerance and high fat-induced hepatic steatosis.

12 asatinib and quercetin (D+Q) reduces overall hepatic steatosis.

13 tissue, decreased gluconeogenesis, and less hepatic steatosis.

14 HIV patients develop hepatic steatosis.

15 d oxidation and lipolysis, and thus promoted hepatic steatosis.

16 ularly among alcohol drinkers and those with hepatic steatosis.

17 pression of adiponectin, but did not prevent hepatic steatosis.

18 ent or even treat the metabolic syndrome and hepatic steatosis.

19 ed impairment of mitochondrial oxidation and hepatic steatosis.

20 abolic disorders, including dyslipidemia and hepatic steatosis.

21 in lean nondrinkers with low genetic risk of hepatic steatosis.

22 iated with blood levels of liver enzymes and hepatic steatosis.

23 sity, insulin resistance, hyperlipidemia and hepatic steatosis.

24 intestinal hypoxia-inducible factor (HIF) in hepatic steatosis.

25 nd fibrosis that are thought to emanate from hepatic steatosis.

26 her analyzed to evaluate their relation with hepatic steatosis.

27 sponse to feeding, exacerbating diet-induced hepatic steatosis.

28 ronger among alcohol drinkers and those with hepatic steatosis.

29 CI: 25, 49) were higher in participants with hepatic steatosis.

30 glucose homeostasis and prevents obesity and hepatic steatosis.

31 lipolysis and prevents high-fat diet-induced hepatic steatosis.

32 ein had significant shared gene effects with hepatic steatosis.

33 esses adipose tissue lipolysis, ameliorating hepatic steatosis.

34 Adult cnr2 mutants are susceptible to hepatic steatosis.

35 obesity-associated abnormalities, including hepatic steatosis.

36 ein B (apoB) lipoproteins but can also cause hepatic steatosis.

37 temic glucose homeostasis, inflammation, and hepatic steatosis.

38 downregulation may contribute to HCV-induced hepatic steatosis.

39 hepatic VLDL secretion that protects against hepatic steatosis.

40 xert anti-inflammatory effects and alleviate hepatic steatosis.

41 rdiac structure, energetics, and cardiac and hepatic steatosis.

42 pression of ER chaperone proteins alleviates hepatic steatosis.

43 re protected against HFD-induced obesity and hepatic steatosis.

44 es improved glucose tolerance and attenuated hepatic steatosis.

45 PPARgamma antagonists may be useful to treat hepatic steatosis.

46 obesity-associated inflammation and improve hepatic steatosis.

47 lesterol levels when fed a diet that induces hepatic steatosis.

48 reased hepatic injury despite an increase in hepatic steatosis.

49 the gold standard for diagnosing and grading hepatic steatosis.

50 atic lipids and mediating susceptibility for hepatic steatosis.

51 eted circulating lipid levels that prevented hepatic steatosis.

52 sterol synthesis lead to LD accumulation and hepatic steatosis.

53 ic disorders from insulin resistance (IR) to hepatic steatosis.

54 ion, systemic dyslipidemia, and reduction of hepatic steatosis.

55 in a dietary mouse model of obesity-mediated hepatic steatosis.

56 nd protects against diet-induced obesity and hepatic steatosis.

57 mosiderosis, cholestasis, and cirrhosis with hepatic steatosis.

58 ce (IR) is associated with hyperglycemia and hepatic steatosis.

59 d disorders such as hypertriglyceridemia and hepatic steatosis.

60 ng plasma nonesterified fatty acids and less hepatic steatosis.

61 c sympathetic nerves reduced obesity-induced hepatic steatosis.

62 mice were protected against fasting-induced hepatic steatosis (a model of enhanced exogenous FA deli

63 echanisms of inhalation exposure to PM2.5 on hepatic steatosis, a precursor or manifestation of metab

64 , HFD-fed AdSod2 KO mice were protected from hepatic steatosis, adipose tissue inflammation, and gluc

65 e proportion of patients without significant hepatic steatosis after 48 weeks was greater for those w

66 sociations between ambient air pollution and hepatic steatosis among 2,513 participants from the Fram

67 hing efavirenz (EFV) to raltegravir (RAL) on hepatic steatosis among HIV-infected patients with nonal

68 e Hedgehog pathway play an important role in hepatic steatosis and beyond.

69 roton density fat fraction (PDFF) in grading hepatic steatosis and change in hepatic steatosis in adu

70 ce were protected against the development of hepatic steatosis and diacylglycerol-PKCepsilon-induced

71 tions in obesity and type 2 diabetes include hepatic steatosis and disruption of glucose-glycogen hom

72 demonstrates that cellular senescence drives hepatic steatosis and elimination of senescent cells may

73 udy examined the shared gene effects between hepatic steatosis and fibrosis and their associations wi

74 Studies have shown that hepatic steatosis and fibrosis are heritable, but whethe

75 bing exogenous hepatic FA use modulates both hepatic steatosis and fibrosis in the setting of hepatic

76 patic lipid metabolism, atherosclerosis, and hepatic steatosis and fibrosis, each of which is pertine

77 cytochrome P4504a14, which is implicated in hepatic steatosis and fibrosis, was substantially reduce

78 had transient elastography (TE) to evaluate hepatic steatosis and fibrosis.

79 ncy virus (HIV) or antiretroviral therapy on hepatic steatosis and fibrosis.

80 d Fgf21 expression and reduced lipid-induced hepatic steatosis and glucose intolerance, but these eff

81 ects of chronic glucagon treatment-reversing hepatic steatosis and glucose intolerance-were abrogated

82 side A significantly improved liver enzymes, hepatic steatosis and hepatic fibrosis.

83 in, insulin resistance, glucose intolerance, hepatic steatosis and hepatic inflammation in diabetic m

84 ced WAT lipolysis, glucocorticoid- initiated hepatic steatosis and hypertriglyceridemia were improved

85 leaner Ppp1r15a mutant animals with reduced hepatic steatosis and improved insulin sensitivity, albe

86 type-specific roles for L-Fabp in mitigating hepatic steatosis and in modulating fibrogenic injury an

87 Here, we show that hepatic steatosis and inflammation display diurnal rhyth

88 FGF21 administration reduced alcohol-induced hepatic steatosis and inflammation in WT mice.

89 tyle diet gained less weight, developed less hepatic steatosis and inflammation, and had a lower mean

90 ween diet, bile acids, sex, and dysbiosis in hepatic steatosis and inflammation.

91 ion significantly attenuates ethanol-induced hepatic steatosis and injury through multiple mechanisms

92 Hepatic steatosis and insulin resistance are among the m

93 t absorption and are protected from obesity, hepatic steatosis and insulin resistance associated with

94 On high-fat diet, JAK2L mice had hepatic steatosis and insulin resistance despite protect

95 in the liver and/or adipose tissue resolved hepatic steatosis and insulin resistance in mice caused

96 s an attractive target for the management of hepatic steatosis and insulin resistance.

97 are protected against high-fat diet-induced hepatic steatosis and insulin resistance.

98 f fat in the liver and reversed diet-induced hepatic steatosis and insulin resistance.

99 ining 3 (PNPLA3) is robustly associated with hepatic steatosis and its progression to steatohepatitis

100 lated events, which are both associated with hepatic steatosis and its progressive form, nonalcoholic

101 patic fatty acid esterification, ameliorates hepatic steatosis and lipid-induced insulin resistance.

102 Mice with high-fat diet-induced simple hepatic steatosis and lipid-loaded Huh7 cells had reduce

103 tion of DES1 may provide a means of treating hepatic steatosis and metabolic disorders.

104 terms of differences in insulin sensitivity, hepatic steatosis and metabolic outcomes in participants

105 BR may be a new therapeutic strategy against hepatic steatosis and non-alcoholic steatohepatitis.

106 ol allows for population-based assessment of hepatic steatosis and nonalcoholic fatty liver disease,

107 ion of Hif2a, in which high-fat-diet-induced hepatic steatosis and obesity were substantially lower a

108 These changes were accompanied by reduced hepatic steatosis and oxidative stress in adipose tissue

109 Praliciguat treatment lowered hepatic steatosis and plasma cholesterol levels.

110 ltivariable quantitative US models to detect hepatic steatosis and quantify hepatic fat.

111 nd liver injury with significantly increased hepatic steatosis and serum AST level as well as hepatic

112 Hepatic steatosis and serum level of liver enzymes, and

113 On chow, JAK2L mice had hepatic steatosis and severe whole-body and hepatic insu

114 emonstrate that, along with HFD, TCS induces hepatic steatosis and steatohepatitis jointly regulated

115 Both of these mutant mouse lines developed hepatic steatosis and subsequent steatohepatitis on a re

116 c link between liver sympathetic outflow and hepatic steatosis and suggest that manipulation of the l

117 ion protects mice from high-fat diet-induced hepatic steatosis and that mutation of the SLC13A5 ortho

118 to circulating metabolites, liver function, hepatic steatosis and the gut microbiome.

119 (S)-MRI-1867 reduced hepatic steatosis and the rate of hepatic VLDL secretion

120 The hepatic steatosis and total-c accumulation in liver were

121 alities, volume, intensity) for treatment of hepatic steatosis, and 4) evidence for a sustained prote

122 tial endocrine disruption, oxidative stress, hepatic steatosis, and adverse drug interactions.

123 and creatinine, caused iWAT hypertrophy and hepatic steatosis, and CAP reversed these.

124 m2 are resistant to diet-induced obesity and hepatic steatosis, and exhibit improved glucose homeosta

125 to the lipotoxicity that underlies diabetes, hepatic steatosis, and heart disease.

126 re protected against diet-induced adiposity, hepatic steatosis, and hyperglycemia.

127 126 ameliorated obesity, insulin resistance, hepatic steatosis, and hyperlipidemia without changes in

128 FD-induced adipose and hepatic inflammation, hepatic steatosis, and insulin resistance.

129 ronic metabolic diseases, including obesity, hepatic steatosis, and insulin resistance.

130 and alanine aminotransferase concentrations; hepatic steatosis; and hepatic expression of IL-1alpha,

131 ce were protected from high-fat diet-induced hepatic steatosis as well as from insulin resistance.

132 ciated with increased odds of improvement in hepatic steatosis, as graded by ultrasound (OR: 2.40; 95

133 iation between HIV infection and severity of hepatic steatosis, as measured by absolute liver attenua

134 EFV to RAL showed decreases in the degree of hepatic steatosis, as measured by CAP, compared with tho

135 tly regulated and excessive lipolysis causes hepatic steatosis, as NEFA released from adipose tissue

136 BBR treatment also decreased hepatic steatosis, as well as the expression of acetyl-C

137 ion with MRI proton density fat fraction for hepatic steatosis assessment in nonalcoholic fatty liver

138 sults in reductions in circulating IGF-1 and hepatic steatosis, associated with systemic insulin resi

139 posure to TBT led to increased adiposity and hepatic steatosis at 14 and 20 weeks of age and increase

140 Changes in hepatic steatosis at 48 weeks of follow-up over baseline

141 between magnesium intake and alcohol use and hepatic steatosis at baseline were not significant (P >

142 There was no difference in hepatic steatosis between groups.

143 We compared the prevalence and severity of hepatic steatosis between HIV-infected (HIV+) and uninfe

144 R of db/db mice reverted insulin resistance, hepatic steatosis, body weight and adiposity to those of

145 ver regeneration protein deficiency promotes hepatic steatosis by inducing oxidative stress and micro

146 report here that liver BVRA protects against hepatic steatosis by inhibiting glycogen synthase kinase

147 idly induces hepatic autophagy and abrogates hepatic steatosis by inhibiting hexose transport via the

148 ut cardiovascular disease, the prevalence of hepatic steatosis by noncontrast abdominal CT was not di

149 also sufficient to prevent hyperglycemia and hepatic steatosis, by enhancing muscle glucose uptake an

150 but was also consistent with lower risk for hepatic steatosis, cardiac hypertrophy, and premature de

151 food allergies, type 1 and type 2 diabetes, hepatic steatosis, cardiovascular disease, and inflammat

152 knockout (Acox1-LKO) protected mice against hepatic steatosis caused by starvation or HFD due to ind

153 Our results suggest that hepatic steatosis causes resistance to the effect of glu

154 & AIMS: Effective treatments are needed for hepatic steatosis characterized by accumulation of trigl

155 e had higher serum EtOH levels and developed hepatic steatosis characterized by micro- and macrovesic

156 ty and metabolic pathways putatively driving hepatic steatosis compared with changes induced by exerc

157 xhibited reduced body weight, adiposity, and hepatic steatosis compared with WT controls.

158 e developed a multi-component classifier for hepatic steatosis comprised of phenotypic, genomic, and

159 agon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis, concentrations of liver enzymes, and

160 bidities (for example, diabetes mellitus and hepatic steatosis) contribute to approximately 2.5 milli

161 own driver of CVD, the mechanism(s) by which hepatic steatosis contributes to CVD remains elusive.

162 od why some, but not other, individuals with hepatic steatosis develop NASH.

163 C1 confers broad spectrum protection against hepatic steatosis development.

164 Hepatic steatosis develops when lipid influx and product

165 induced Zip14 KO mice show greater levels of hepatic steatosis due to higher expression of genes invo

166 CREBH-deficient mice developed severe hepatic steatosis due to increased adipose tissue lipoly

167 timulation contributes to the development of hepatic steatosis, dyslipidemia and hyperglycemia.

168 rodent diets with citrus flavonoids prevents hepatic steatosis, dyslipidemia, and insulin resistance

169 ubsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin re

170 The primary outcome was change in hepatic steatosis estimated by magnetic resonance imagin

171 Our study comprised 8,345 persons with hepatic steatosis (fatty liver index >60) who participat

172 dation in vivo partially protected mice from hepatic steatosis, fibrosis and inflammation.

173 ion profiles in a group of mouse models with hepatic steatosis, fibrosis, inflammation, and, conseque

174 The mean decrease in hepatic steatosis from baseline to week 8 was significan

175 nction and ameliorates high-fat-diet-induced hepatic steatosis, glucose tolerance, and insulin resist

176 Pancreatic PDFF correlated with hepatic steatosis grades (R(S)=0.573, p<0.001) and hepat

177 gnosed NAFLD and evidence of active disease (hepatic steatosis >10% and alanine aminotransferase leve

178 aerobic capacity had no impact on WD-induced hepatic steatosis; however, rats bred for low aerobic ca

179 The lipids stored in hepatic steatosis (HS) are primarily triglycerides (TGs)

180 Hepatic steatosis (HS) is common in individuals with hep

181 CBC reduced body weight gain, inflammation, hepatic steatosis, hyperglycemia, glucose intolerance, a

182 ivation of Tm6sf2 in mice is associated with hepatic steatosis, hypocholesterolemia, and transaminiti

183 enuation parameter (CAP) in the diagnosis of hepatic steatosis in a series of overweight or obese chi

184 ) in grading hepatic steatosis and change in hepatic steatosis in adults with nonalcoholic steatohepa

185 de novo ceramide synthesis reduced PLIN2 and hepatic steatosis in alcohol-fed mice, but only de novo

186 missible protection against fructose-induced hepatic steatosis in association with a bloom in Akkerma

187 rately, forced PHLPP2 expression ameliorates hepatic steatosis in diet-induced obese mice.

188 improved lipid metabolism, and also reduced hepatic steatosis in diet-induced obese mice.

189 Finally, E2f1 deletion completely abrogated hepatic steatosis in different murine models of nonalcoh

190 stress and markers of liver fibrosis but not hepatic steatosis in DKO mice.

191 esent an important factor in pathogenesis of hepatic steatosis in HH.

192 However, PM2.5 exposure relieved hepatic steatosis in high-fat diet-induced obese mice.

193 ic actions mitigating insulin resistance and hepatic steatosis in high-fat-sucrose diet (HFS) induced

194 viral drugs with a lower potential to induce hepatic steatosis in human immunodeficiency virus (HIV)

195 The absence of hepatic steatosis in L-Them2(-/-) mice fed chow was expl

196 We sought to determine the role of FGF21 in hepatic steatosis in mice exposed to chronic alcohol tre

197 NF6 in livers of adult C57Bl/6 mice leads to hepatic steatosis in mice fed normal laboratory chow.

198 ne, a natural compound that protects against hepatic steatosis in mice fed the high-fat diet, as a no

199 ls, increased fat mass and dyslipidemia, and hepatic steatosis in mice lacking C/EBP homologous prote

200 otective against high fat diet (HFD)-induced hepatic steatosis in mice through suppression of hepatic

201 overexpression of RBP4 was reported to cause hepatic steatosis in mice.

202 SLC7A11 was associated with reduced risk of hepatic steatosis in participants (odds ratio, 0.69; 95%

203 Pancreatic fat deposition correlates with hepatic steatosis in patients with chronic NALD, but not

204 revents the development of hyperglycemia and hepatic steatosis in response to GCs.

205 Both diets induced severe hepatic steatosis in the LTKO mice as compared to WT con

206 or diagnostic tests have been developed for hepatic steatosis in the setting of obesity.

207 ressed adipose tissue lipolysis and improved hepatic steatosis in these mice.

208 We investigated hepatic steatosis in transgenic mice expressing the HIV-

209 Clinical remission rate (achieving grade 0 hepatic steatosis) in HP-diet and beta-cryptoxanthin gro

210 s on fatty liver index (FLI), a biomarker of hepatic steatosis, in a population-based cross-sectional

211 nce; potential explanations for reduction in hepatic steatosis include reductions in adipose lipolysi

212 f lipid dysregulation that can contribute to hepatic steatosis, including reduced triglyceride secret

213 on of 18:2 species with complete reversal of hepatic steatosis, increased hepatic injury, and worsene

214 CD36Tg mice showed unexpected attenuation of hepatic steatosis, increased very low-density lipoprotei

215 fed wild-type and Sirt1-LKO mice in reducing hepatic steatosis, increasing fatty acid beta-oxidation,

216 Moreover, exercise can effectively reduce hepatic steatosis independent of changes in body mass.

217 s indexes (BMI), fatty liver index (FLI) and hepatic steatosis index (HSI) was analyzed using the imp

218 on a previously validated biochemical model (Hepatic Steatosis Index).

219 reduced obesity development and ameliorated hepatic steatosis induced by both high-fat diet treatmen

220 es, is required for hypertriglyceridemia and hepatic steatosis induced by the synthetic glucocorticoi

221 ation of pNaKtide reduced obesity as well as hepatic steatosis, inflammation and fibrosis.

222 e spontaneously developed liver disease with hepatic steatosis, inflammation, and degeneration.

223 ged as a key regulator in the maintenance of hepatic steatosis, inflammation, and fibrosis.

224 c steatohepatitis (NASH) is characterised by hepatic steatosis, inflammation, hepatocellular injury,

225 FLD and the impact of AMPK activity state on hepatic steatosis, inflammation, liver injury, and fibro

226 ssociated fatty liver and insulin resistance.Hepatic steatosis is a common disease closely associated

227 ociated lipid metabolic disorders.IMPORTANCE Hepatic steatosis is a frequent complication associated

228 In this study, we found that hepatic steatosis is associated with robust hepatic symp

229 Hepatic steatosis is caused by metabolic imbalances that

230 Hepatic steatosis is characterised by excessive triglyce

231 Moderate-to-severe hepatic steatosis is less common in PWH compared with de

232 Hepatic steatosis is linked to increased risk for insuli

233 Hepatic steatosis is prevalent in Western countries, but

234 Hepatic steatosis is strongly associated with cardiovasc

235 bution of each hormone to the development of hepatic steatosis is unclear.

236 n part by elevated liver triglycerides (i.e. hepatic steatosis), is a growing health problem.

237 ssociated with markers of liver function and hepatic steatosis, laying the groundwork for future diag

238 rated and provided significant reductions in hepatic steatosis, liver biochemistry, and serum bile ac

239 models and prevalence ratios for presence of hepatic steatosis (LPR </= 0.33) using generalized linea

240 ompared the prevalence of moderate-to-severe hepatic steatosis (M-HS) in PWH with human immunodeficie

241 Hepatic steatosis may be benign or progress to hepatocyt

242 asis of this knowledge, we hypothesized that hepatic steatosis might impair glucagon's action on hepa

243 ide important mechanistic insights as to how hepatic steatosis modulates lipid regulatory genes, incl

244 Compared to patients with hepatic steatosis/normal ALT, those with steatosis/eleva

245 t2 knockout mice are leaner and resistant to hepatic steatosis, obesity and insulin resistance under

246 represent an effective therapy for managing hepatic steatosis, obesity, and diabetes.

247 the present study we examined the effect of hepatic steatosis on LDLR expression and circulating LDL

248 of excess adiposity, insulin resistance, and hepatic steatosis on the complex integration of insulin

249 In the U.S. population, severe hepatic steatosis on ultrasound and liver enzyme elevati

250 re not protected against excess weight gain, hepatic steatosis or glucose intolerance, they exhibited

251 each score specifying microbial metabolism, hepatic steatosis, oxidative stress, nitric oxide modula

252 IBO was also not associated with significant hepatic steatosis (p = 0.951; PR = 0.951; CI 95% [0.452-

253 d catabolism, leads to AT atrophy and severe hepatic steatosis, phenotypes rescued by macrophage-spec

254 Other changes in the liver included hepatic steatosis, portal fibrosis, lymphocytic infiltra

255 al: -0.006, -0.001) and higher prevalence of hepatic steatosis (prevalence ratio = 1.16, 95% confiden

256 To compare pancreatic and hepatic steatosis quantified by proton density fat fract

257 Hepatic steatosis renders liver more vulnerable to ische

258 The results of this study suggest that hepatic steatosis results in hyperammonemia, which is as

259 this study had a high prevalence of elevated hepatic steatosis scores.

260 d units; p < 0.001), correlating with lesser hepatic steatosis severity, compared to uninfected parti

261 calcipotriol reduced liver inflammation and hepatic steatosis, significantly improving insulin sensi

262 ere still protected against fructose-induced hepatic steatosis, suggesting that changes in microbiota

263 in the transgenic adi-hRBP4 murine model of hepatic steatosis, suggesting that RBP4 antagonists may

264 f livers revealed that asparaginase provoked hepatic steatosis that coincided with activation of anot

265 sive hepatic triglyceride accumulation (i.e. hepatic steatosis), the incidence of NAFLD is increasing

266 Hepatic steatosis, the excess storage of intrahepatic li

267 IL-1-type cytokines can regulate hepatic steatosis; the NLR family pyrin domain containin

268 inal HIF-2alpha could be a viable target for hepatic steatosis therapy.

269 bile acid composition and in fasting-induced hepatic steatosis through a novel mechanism involving ac

270 sulinemia resulted in insulin resistance and hepatic steatosis through activation of LXR.

271 multiple loci that confer susceptibility to hepatic steatosis through diverse metabolic mechanisms.

272 -expression of PNPLA8 dramatically decreases hepatic steatosis through increased autophagy in hepatoc

273 is the development of insulin resistance and hepatic steatosis through inhibition of the transcriptio

274 reveal a novel function of SRA in promoting hepatic steatosis through repression of ATGL expression.

275 in the liver delineates the transition from hepatic steatosis to steatohepatitis (SH).

276 lic fatty liver diseases (NAFLD) ranges from hepatic steatosis to steatohepatitis and fibrosis.

277 ggesting a possible specific contribution of hepatic steatosis to subclinical vascular impairment.

278 topathologic features, ranging from isolated hepatic steatosis, to steatohepatitis with evidence of h

279 FFA contributes to both gluconeogenesis and hepatic steatosis.TRIAL REGISTRATIONClinicalTrials.gov N

280 Thus, PLD1 plays an important role in hepatic steatosis via the regulation of autophagy.

281 Hepatic steatosis was assessed at baseline and after 72

282 Moderate-to-severe hepatic steatosis was assessed by unenhanced computed to

283 Hepatic steatosis was assessed with magnetic resonance i

284 Hepatic steatosis was defined by noncontrast computed to

285 Hepatic steatosis was effectively reduced only in ob/ob

286 rthermore, established high fat diet-induced hepatic steatosis was effectively reduced with pharmacol

287 mice (Mttp-LKO, i.e., double knockout mice) hepatic steatosis was greatly diminished and fibrosis pr

288 t of PM2.5 exposure on high-fat diet-induced hepatic steatosis was mediated through PM2.5-induced hep

289 Hepatic steatosis was significantly more frequent in HH.

290 scular disease, patchy cardiac fibrosis, and hepatic steatosis, was noted in the other organs.

291 Serum levels of liver enzymes and grade of hepatic steatosis were assessed at baseline and study en

292 The detrimental effects of ENDS on hepatic steatosis were associated with significantly gre

293 ory to weight gain, glucose intolerance, and hepatic steatosis when challenged with high-fat diet.

294 accurately classifies grades and changes in hepatic steatosis when histologic analysis of biopsies i

295 g and fasting blood glucose, weight gain and hepatic steatosis while protecting against diabetic neur

296 mass, fat content, glucose intolerance, and hepatic steatosis with advancing age.

297 Patients with hepatic steatosis with persistently normal ALT are at lo

298 Y is also a target against dyslipidaemia and hepatic steatosis, with a compound currently in phase 3

299 e protected against dietary fructose-induced hepatic steatosis, without weight loss or changes in ene

300 triglyceride transfer protein (Mttp) causes hepatic steatosis, yet the risks for developing hepatic